法国绝经后女性队列中双膦酸盐使用与乳腺癌风险
在法国E3N前瞻性队列64,438名绝经后女性中,2004至2011年平均随访7.2年,发现2,407例首次原发性乳腺癌。双膦酸盐暴露与乳腺癌风险的HR为0.98(95%CI 0.85-1.12),未发现与乳腺癌发病率降低相关。
要点
- 双膦酸盐暴露与乳腺癌风险无关,HR 0.98(95%CI 0.85-1.12)。
- 风险降低仅限于治疗开始后第一年(HR 0.56;95%CI 0.36-0.87),可能由健康筛查者偏倚解释。
- 未发现按年龄、BMI、绝经时间、激素替代治疗、钙剂或维生素D补充的效应修饰。
核心结论
- 在2004至2011年观察的绝经后女性观察性队列中,双膦酸盐使用(可能为骨质疏松管理而处方)与乳腺癌发病率降低无关。
研究设计与样本
- 研究人群为参与法国E3N前瞻性队列的64,438名绝经后女性,数据来自每两年一次的自报问卷并与药品报销数据库匹配。
- 随访期间双膦酸盐暴露及其他骨质疏松治疗使用由报销数据确定,其他协变量来自问卷。
- 使用Cox比例风险模型估计乳腺癌风险比(HR),暴露作为时变变量处理。
主要发现
- 平均随访7.2年(2004至2011年)期间,共识别2,407例首次原发性乳腺癌。
- 双膦酸盐暴露与乳腺癌风险的HR为0.98(95%CI 0.85-1.12)。
- 未发现年龄、体重指数、绝经时间、激素替代治疗使用、钙剂补充或维生素D补充对效应有修饰作用。
- 不同双膦酸盐分子间无异质性,且无按累积剂量、使用时长或末次使用后时间的趋势。
- 观察到乳腺癌风险降低仅限于治疗开始后第一年(HR 0.56;95%CI 0.36-0.87),可能由健康筛查者偏倚解释。
临床怎么用
- 原文未据此给出推荐。
局限性
- 风险降低仅限于治疗开始后第一年(HR 0.56;95%CI 0.36-0.87),可能由健康筛查者偏倚解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To assess whether bisphosphonate (BP) use is associated with decreased breast cancer incidence in a cohort of postmenopausal women. Methods The study population included 64,438 postmenopausal women participating in the French E3N (Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale) prospective cohort, with data self-reported in biennial questionnaires matched with data from a drug reimbursement database. Exposure to BPs and the use of other osteoporosis treatments during follow-up were determined using reimbursement data. Other covariates (breast cancer risk factors, clinical risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the questionnaires. Hazard ratios (HRs) of breast cancer were estimated using Cox proportional hazards models, considering exposure as a time-varying variable. Results Over an average of 7.2 years of follow-up (2004 to 2011), 2,407 first primary breast cancer cases were identified. The HR of breast cancer associated with exposure to BPs was 0.98 (95% CI, 0.85 to 1.12). We found no effect modification by age, body mass index, time since menopause, use of hormone replacement therapy, use of calcium supplements, or use of vitamin D supplements. There was no heterogeneity across BP molecules and no trend according to cumulative dose, duration of use, or time since last use. We observed a decrease in breast cancer risk restricted to the year after treatment initiation (HR, 0.56; 95% CI, 0.36 to 0.87), which was likely explained by healthy screenee bias. Finally, we did not find any variation in HRs across breast carcinomas defined by their estrogen receptor or invasive or in situ status. Conclusion In our observational cohort of postmenopausal women observed from 2004 to 2011, BP use, likely prescribed for the management of osteoporosis, was not associated with decreased breast cancer incidence.
引用
- Fournier A, Mesrine S, Gelot A, et al. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. J Clin Oncol. 2017. PMID: 28708471. doi:10.1200/JCO.2016.71.4337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。